Dogwood Therapeutics (NASDAQ:DWTX) Releases Quarterly Earnings Results

Dogwood Therapeutics (NASDAQ:DWTX) issued its earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, FiscalAI reports.

Dogwood Therapeutics Trading Down 7.8%

DWTX opened at $2.97 on Thursday. Dogwood Therapeutics has a 1-year low of $2.60 and a 1-year high of $9.50. The stock has a market capitalization of $95.28 million, a PE ratio of -0.12 and a beta of 1.90. The firm has a 50-day moving average price of $2.96 and a two-hundred day moving average price of $4.69.

Institutional Trading of Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. 9.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on DWTX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a report on Friday, February 20th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.